Zhongzhi Pharmaceutical Holdings Limited (3737.HK)
HKD 0.89
(-2.2%)
HKD 0.89
(-2.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 60.69 Million CNY | 128.88% |
| 2022 | -210.15 Million CNY | -264.59% |
| 2021 | -57.64 Million CNY | 45.69% |
| 2020 | -106.12 Million CNY | 58.02% |
| 2019 | -252.82 Million CNY | 18.26% |
| 2018 | -309.29 Million CNY | 8.94% |
| 2017 | -339.65 Million CNY | -4.15% |
| 2016 | -326.13 Million CNY | 23.56% |
| 2015 | -426.63 Million CNY | -892.09% |
| 2014 | -43 Million CNY | -908.77% |
| 2013 | -4.26 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -88.34 Million CNY | -41.1% |
| 2023 Q4 | 60.69 Million CNY | 250.27% |
| 2023 FY | 60.69 Million CNY | 128.88% |
| 2023 Q2 | -40.38 Million CNY | 80.78% |
| 2022 FY | -210.15 Million CNY | -264.59% |
| 2022 Q2 | -91.29 Million CNY | -58.39% |
| 2022 Q4 | -210.15 Million CNY | -130.19% |
| 2021 Q2 | -12.49 Million CNY | 88.23% |
| 2021 FY | -57.64 Million CNY | 45.69% |
| 2021 Q4 | -57.64 Million CNY | -361.27% |
| 2020 FY | -106.12 Million CNY | 58.02% |
| 2020 Q4 | -106.12 Million CNY | 49.89% |
| 2020 Q2 | -211.79 Million CNY | 16.23% |
| 2019 FY | -252.82 Million CNY | 18.26% |
| 2019 Q4 | -252.82 Million CNY | -52.63% |
| 2019 Q2 | -165.65 Million CNY | 46.44% |
| 2018 Q4 | -309.29 Million CNY | -247.21% |
| 2018 FY | -309.29 Million CNY | 8.94% |
| 2018 Q2 | -89.07 Million CNY | 73.77% |
| 2017 Q4 | -339.65 Million CNY | -67.2% |
| 2017 Q2 | -203.14 Million CNY | 37.71% |
| 2017 FY | -339.65 Million CNY | -4.15% |
| 2016 Q2 | -123.06 Million CNY | 71.16% |
| 2016 Q4 | -326.13 Million CNY | -165.02% |
| 2016 FY | -326.13 Million CNY | 23.56% |
| 2015 Q4 | -426.63 Million CNY | -2440.72% |
| 2015 FY | -426.63 Million CNY | -892.09% |
| 2015 Q2 | -16.79 Million CNY | 60.95% |
| 2014 Q4 | -43 Million CNY | 0.0% |
| 2014 FY | -43 Million CNY | -908.77% |
| 2013 FY | -4.26 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 123.46% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 97.013% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | -921.08% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 79.872% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | 418.799% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | -96.113% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 127.685% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 76.307% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 83.924% |
| SSY Group Limited | 1.71 Billion HKD | 96.458% |
| JBM (Healthcare) Limited | -7.39 Million HKD | 920.287% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 82.014% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 99.881% |